IL-2 has been used as monotherapy and in combination with chemotherapy or biologics for the treatment of cancer with significant clinical benefit for melanoma and renal cell carcinoma patients [48]. This evidence concerns the gene IL2 and hereditary clear cell renal cell carcinoma.